NYRADA INC.

2.52%

29.0¢

Market Cap $68.92M

Healthcare Biotechnology

Nyrada Inc is an Australia-based drug development company. The Company focuses on... Nyrada Inc is an Australia-based drug development company. The Company focuses on development of small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. Its drug development programs include a proprotein convertase subtilisin/kexin type nine (PCSK9) inhibitor for the treatment of high blood low-density lipoprotein (LDL)-cholesterol levels in patients poorly responsive to or unable to take statin drugs. It develops a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury. The Company also develops a drug to treat pain associated with peripheral nerve damage and autoimmune diseases such as psoriasis.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Latest Threads

Tag

Subject

NYR

Ann: Positive Final Review of Nyrada Phase I Clinical Trial

14:08

3.0K

14:08

Last post Bendunstan

3.0K

NYR

Ann: Nyrada Half Year Results FY2025

2 3

11/08/25

152

40K

11/08/25

Last post Bendunstan

152

40K

NYR

Ann: Cleansing Statement

11/08/25

196

11/08/25

Last post

ASX News

196

NYR

Ann: Application for quotation of securities - NYR

11/08/25

165

11/08/25

Last post

ASX News

165

NYR

CHART

2 3 4

09/08/25

198

38K

09/08/25

Last post Bendunstan

198

38K

NYR

Ann: Final Phase I Clinical Trial Patients Dosed and Discharged

06/08/25

23K

06/08/25

Last post Bendunstan

23K

NYR

Ann: BioShares Biotech Summit Presentation

06/08/25

287

06/08/25

Last post

ASX News

287

NYR

Ann: Change in substantial holding - M Azzi

05/08/25

1.5K

05/08/25

Last post Bendunstan

1.5K

See All Discussions

Timeline

Cleansing Statement
11 Aug 09:53	Share

Application for quotation of securities - NYR
11 Aug 09:52	Share

Positive Final Review of Nyrada Phase I Clinical Trial
06 Aug 09:38	Share

BioShares Biotech Summit Presentation
06 Aug 08:24	Share

Change in substantial holding - M Azzi
05 Aug 10:25	Share

Cleansing Statement
04 Aug 11:15	Share

Application for quotation of securities - NYR
04 Aug 11:13	Share

Application for quotation of securities - NYR
04 Aug 11:10	Share

Proposed issue of securities - NYR
04 Aug 09:05	Share

Proposed issue of securities - NYR
04 Aug 09:05	Share

Nyrada Successfully Raises $8.25 Million via Placement
04 Aug 09:05	Share

Change in substantial holding - M Azzi
31 Jul 12:44	Share

Trading Halt
31 Jul 09:16	Share

Quarterly Activities Report and Appendix 4C
31 Jul 08:40	Share

Top 20 CDI Holder List
31 Jul 08:29	Share

NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
23 Jul 08:30	Share

Final Phase I Clinical Trial Patients Dosed and Discharged
21 Jul 08:26	Share

Final Nyrada Phase I Clinical Trial Cohort to Commence
14 Jul 09:14	Share

Notice of Change of Interests of Substantial Holder - M Azzi
04 Jul 11:09	Share

Proposed issue of securities - NYR
30 Jun 08:31	Share

Notice of Change of Interests of Substantial Holder - M Azzi
25 Jun 12:15	Share

Phase I Clinical Trial Dosing Update No 4
16 Jun 08:46	Share

Nyrada Investor Conference Call
16 Jun 08:38	Share

Non-Deal Investor Presentation
16 Jun 08:30	Share

Change of Director's Interest Notice - RW
13 Jun 09:20	Share

Change of Director's Interest Notice - MF
13 Jun 09:19	Share

Change of Director's Interest Notice - CC
13 Jun 09:18	Share

Change of Director's Interest Notice - JM
13 Jun 09:18	Share

Notification of cessation of securities - NYR
13 Jun 09:09	Share

Notice of Change of Interests of Substantial Holder - M Azzi
12 Jun 08:31	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 29.0¢		Change -0.008(2.52%)		Mkt cap ! $68.92M

Open	High	Low	Value	Volume
29.5¢	29.5¢	28.0¢	$148.9K	511.8K

Buyers (Bids)

No.	Vol.	Price($)
1	2500	29.0¢

Sellers (Offers)

Price($)	Vol.	No.
29.5¢	9521	2

View Market Depth

No.	Vol.	Price($)
1	2500	0.290
5	59882	0.280
2	10579	0.275
1	5091	0.270
1	100000	0.265

Price($)	Vol.	No.
0.295	9521	2
0.300	259493	4
0.310	29700	1
0.320	38150	2
0.325	75000	1

Last trade - 13.51pm 12/08/2025 (20 minute delay)


Last 29.5¢		Change -0.008 ( 0.00 %)
Open	High	Low	Volume
28.5¢	29.5¢	28.5¢	157636
Last updated 15.23pm 12/08/2025 ?

NYR (ASX) Chart

NYRADA INC.

Latest Threads

Timeline

Featured News

Latest Articles

Nyrada pushes through to third cohort in Phase 1 trial for NYR-BI03

Nyrada Inc has been given the go-ahead to a third cohort in its Phase 1 clinical trial into its drug for neuroprotection and cardioprotection

Study finds Nyrada's lead drug can prevent secondary brain injury

Nyrada Inc has reported strong results from a collaborative study it has been engaged in regarding its lead candidate NYR-BI03

Nyrada doses first cohort in trial to assess neuroprotective, cardioprotective drug

Nyrada Inc has dosed the first cohort of patients in its Phase I first-in-human trial to assess the safety and tolerability of NYR-BI03

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News